Literature DB >> 15760070

Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique.

Mukesh Gohel1, Madhabhai Patel, Avani Amin, Ruchi Agrawal, Rikita Dave, Nehal Bariya.   

Abstract

The purpose of this research was to develop mouth dissolve tablets of nimesulide. Granules containing nimesulide, camphor, crospovidone, and lactose were prepared by wet granulation technique. Camphor was sublimed from the dried granules by exposure to vacuum. The porous granules were then compressed. Alternatively, tablets were first prepared and later exposed to vacuum. The tablets were evaluated for percentage friability, wetting time, and disintegration time. In the investigation, a 32 full factorial design was used to investigate the joint influence of 2 formulation variables: amount of camphor and crospovidone. The results of multiple linear regression analysis revealed that for obtaining a rapidly disintegrating dosage form, tablets should be prepared using an optimum concentration of camphor and a higher percentage of crospovidone. A contour plot is also presented to graphically represent the effect of the independent variables on the disintegration time and percentage friability. A checkpoint batch was also prepared to prove the validity of the evolved mathematical model. Sublimation of camphor from tablets resulted in superior tablets as compared with the tablets prepared from granules that were exposed to vacuum. The systematic formulation approach helped in understanding the effect of formulation processing variables.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15760070      PMCID: PMC2750260          DOI: 10.1208/pt050336

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  8 in total

1.  Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity.

Authors:  Y Bi; H Sunada; Y Yonezawa; K Danjo; A Otsuka; K Iida
Journal:  Chem Pharm Bull (Tokyo)       Date:  1996-11       Impact factor: 1.645

2.  Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes.

Authors:  G Piel; B Pirotte; I Delneuville; P Neven; G Llabres; J Delarge; L Delattre
Journal:  J Pharm Sci       Date:  1997-04       Impact factor: 3.534

3.  A new tablet disintegrating agent: cross-linked polyvinylpyrrolidone.

Authors:  S S Kornblum; S B Stoopak
Journal:  J Pharm Sci       Date:  1973-01       Impact factor: 3.534

Review 4.  Nimesulide: some pharmaceutical and pharmacological aspects--an update.

Authors:  A K Singla; M Chawla; A Singh
Journal:  J Pharm Pharmacol       Date:  2000-05       Impact factor: 3.765

5.  Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems.

Authors:  Buchi N Nalluri; K P R Chowdary; K V R Murthy; A R Hayman; G Becket
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

6.  The anti-inflammatory drug nimesulide inhibits neutrophil adherence to and migration across monolayers of cytokine-activated endothelial cells.

Authors:  P Dapino; L Ottonello; F Dallegri
Journal:  Respiration       Date:  1994       Impact factor: 3.580

Review 7.  Prostaglandins, NSAIDs, and cytoprotection.

Authors:  J L Wallace
Journal:  Gastroenterol Clin North Am       Date:  1992-09       Impact factor: 3.806

8.  Solubility enhancement of Cox-2 inhibitors using various solvent systems.

Authors:  N Seedher; S Bhatia
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

  8 in total
  29 in total

1.  Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion.

Authors:  Omaima A Sammour; Mohammed A Hammad; Nagia A Megrab; Ahmed S Zidan
Journal:  AAPS PharmSciTech       Date:  2006-06-16       Impact factor: 3.246

2.  Optimization studies on design and evaluation of orodispersible pediatric formulation of indomethacin.

Authors:  Jashanjit Singh; Anil K Philip; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2008-01-09       Impact factor: 3.246

3.  Modified polysaccharides as fast disintegrating excipients for orodispersible tablets of roxithromycin.

Authors:  Vijay Sharma; Anil K Philip; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2008-01-15       Impact factor: 3.246

4.  Meloxicam taste-masked oral disintegrating tablet with dissolution enhanced by ion exchange resins and cyclodextrin.

Authors:  Wipada Samprasit; Prasert Akkaramongkolporn; Tanasait Ngawhirunpat; Theerasak Rojanarata; Praneet Opanasopit
Journal:  AAPS PharmSciTech       Date:  2013-07-09       Impact factor: 3.246

5.  Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.

Authors:  Howida Kamal Ibrahim; Doaa A El-Setouhy
Journal:  AAPS PharmSciTech       Date:  2010-01-29       Impact factor: 3.246

6.  Formulation and optimization of orodispersible tablets of diazepam.

Authors:  Khalid K Abed; Ahmed A Hussein; Mowafaq M Ghareeb; Alaa A Abdulrasool
Journal:  AAPS PharmSciTech       Date:  2010-03-16       Impact factor: 3.246

7.  Formulation design and optimization of novel taste masked mouth-dissolving tablets of tramadol having adequate mechanical strength.

Authors:  Ashwini R Madgulkar; Mangesh R Bhalekar; Rahul R Padalkar
Journal:  AAPS PharmSciTech       Date:  2009-05-14       Impact factor: 3.246

8.  Formulation design and optimization of fast dissolving clonazepam tablets.

Authors:  S B Shirsand; Sarasija Suresh; P V Swamy
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

9.  Optimization of fast dissolving etoricoxib tablets prepared by sublimation technique.

Authors:  D M Patel; M M Patel
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

10.  Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique.

Authors:  Punit P Shah; Rajashree C Mashru
Journal:  AAPS PharmSciTech       Date:  2008-03-20       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.